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Aim To assess the toxicity, tolerance, steroid-sparing ca-
pacity, effectiveness, and response rate to imatinib and da-
satinib for the treatment of severe sclerotic chronic graft-
vs-host disease (scGVHD).
Methods This retrospective study analyzed 8 consecutive 
patients with severe refractory scGVHD who received sal-
vage therapy with imatinib. Patients intolerant and/or re-
fractory to imatinib received dasatinib treatment.
Results 7 patients discontinued imatinib treatment (1 
achieved complete response, 5 were resistant and/or in-
tolerant, and 1 developed grade IV neutropenia) and 1 pa-
tient achieved prolonged partial response, but died due to 
an infectious complication while on treatment. 5 patients 
started dasatinib treatment (3 achieved partial responses 
and discontinued dasatinib, 1 achieved a durable partial 
response, but died due to a consecutive rapid pulmonary 
cGVHD progression and 1 with stable disease discontinued 
treatment due to gastroenteric intolerance). The response 
rate (partial and/or complete responses) for severe scGVHD 
was 25% for imatinib and 60% for dasatinib.
Conclusion In our series, dasatinib was better tolerated, 
safer, steroid-sparing, and had a low incidence of infectious 
complications, which suggests that it may be a more ef-
fective therapeutic alternative for patients with refractory 
scGVHD than imatinib. Treatment of scGVHD with effective 
antifibrotic drugs such as TKI, which block the kinase fibrot-
ic pathway, may be a safe and effective therapeutic option, 
but further studies are needed to confirm our findings.
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Chronic graft-vs-host disease (cGHVD) is the major cause 
of late nonrelapse morbidity after allogeneic blood and 
marrow transplantation (1,2), occurring in approximately 
50% of long-term survivors (3,4). Sclerotic chronic graft-
vs-host disease (scGVHD) is one of the most severe forms 
of the disease, involved in the formation of a wide spec-
trum of fibrotic entities, in which the common cause of 
end-organ dysfunction is the excessive production of ex-
tracellular matrix by activated myofibroblasts (5). Inamoto 
et al showed the incidence of scGVHD after three years of 
initial systemic treatment for cGVHD to be 20% (3); oth-
er studies have reported rates ranging from 8% after two 
years of allogeneic transplant to 15% after five years in pa-
tients with cGVHD (4,6).
ScGVHD has limited and disappointing treatment options 
and is associated with considerable functional disability and 
morbidity, impaired quality of life, and prolonged pharma-
cological immunosuppression (3), leading to an additional 
increased risk of infections and other late complications.
Imatinib mesylate is a first generation tyrosine kinase in-
hibitor (TKI), successfully used in patients with bcr-abl pos-
itive leukemias (7,8), which inhibits profibrotic cytokines, 
transforming growth factor-β (TGF-β), and platelet-derived 
growth factor receptor (PDGFR) signaling pathways in ad-
dition to c-Abl (5). It has been shown to decrease fibrosis 
in preclinical models (9), phase II trials, and small cohorts of 
cGVHD patients (10-15).
Dasatinib is a second-generation TKI with a greater inhibi-
tory potency, an improved toxicity profile, and proven clin-
ical efficacy in the treatment of chronic myeloid leukemia 
patients refractory or intolerant to imatinib (16). It inhibits 
sarcoma-tyrosine (Src) kinases, which regulate c-Abl and 
are activated by TGF-β and PDGF (5), play a central role in 
the development of experimental dermal fibrosis (17), and 
effectively inhibit the synthesis of extracellular matrix in 
both in vitro and in vivo models (18). Moreover, dasatinib 
modulates myofibroblast differentiation through Src path-
way, which makes it a potential therapeutic option for the 
treatment of fibrotic diseases (19).
Owing to their antifibrotic effects by blocking kinase fi-
brotic targets and their signaling pathways, we hypoth-
esized that imatinib and dasatinib may be effective ther-
apeutic alternatives for patients with scGVHD. We have 
already reported in a small series of patients the first di-
rect clinical evidence suggesting that dasatinib may be 
a safe and effective therapeutic option for patients 
with severe scGVHD refractory to corticosteroids and re-
sistant or intolerant to imatinib (20). Here, in a larger series 
of patients with longer follow-up, we evaluated the tox-
icity, tolerance, steroid-sparing capacity, effectiveness, and 
response rate to imatinib and dasatinib for the treatment 
of severe scGVHD.
PAtIentS AnD MethODS
We retrospectively described a series of 8 consecutive pa-
tients with severe scGVHD in whom at least two previous 
immunosuppressive treatment lines failed (Table 1) and 
who went on to receive salvage therapy with imatinib. Pa-
tients were treated at the Catalan Institute of Oncology, 
Barcelona, between January 2009 and December 2015. 
5 patients were intolerant and/or refractory to imatinib 
and received dasatinib treatment. The median age at al-
logeneic transplantation was 53 (range, 27-67) years, the 
median time from allogeneic transplant was 23 months 
(range, 19-108), and the median time from scGVHD diag-
nosis was 18.5 months (range, 11-26). 7 patients presented 
with de novo chronic GVHD (87.5%). Patients’, transplant, 
and cGVHD characteristics are summarized in Table 1.
The study was approved by the Ethics Committee of Cata-
lan Institute of Oncology, Duran i Reynals Hospital, Barce-
lona and informed consent for off-label use of the drugs 
was given by all patients. Imatinib was started at a dose of 
100 mg daily and in the absence of severe toxicity or intol-
erance escalated to 400 mg daily within 8 weeks. Dasatinib 
was started at a dose of 50 mg daily and in the absence of 
severe toxicities the dose was escalated to 100 mg daily 
within 8 weeks. Adverse events were graded according to 
the Common Terminology Criteria for Adverse Events, Ver-
sion 4.0. (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/ctc.htm#ctc_40). Supportive care, 
antimicrobial prophylaxis, and monitoring followed our 
standard protocols in keeping with international guide-
lines (21). Diagnoses other than scGVHD, including infec-
tions and drug reactions, were previously excluded and 
sclerodermatous features were histologically confirmed 
by skin biopsy (data not shown). Diagnosis and staging of 
scGVHD were performed according to the National Insti-
tutes of Health Consensus Conference on cGHVD (22), but 
reassessed and graded again according to the updated 
2014 criteria (23) for the purpose of this study. Before the 
start of first and second generation TKI treatment, patients’ 
skin score, joint mobility, range of motion, global severity 
score, and Karnofsky Performance Status were determined, 
and any other possible site involvement was evaluated and 
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graded. The chronic GVHD organ specific severity scores 
and response to TKI at every affected site were graded ac-
cording to the National Institutes of Health Consensus De-
velopment Project on cGVHD (24) and evaluated at three 
monthly intervals from the start of treatment.
ReSultS
Before the start of TKI treatment, all 8 patients had severe 
chronic GVHD (23). Global and organ-specific severity 
scores at the start of TKI treatment (PRE) and at the time 
of withdrawal or death (POST) are shown in Table 2. Se-
vere scoring was attributable to multiple severe organ in-
volvement in 6 patients and single skin involvement in 2 
patients. All 8 patients exhibited severe skin involvement 
with sclerotic features including deep tissue sclerosis and 
hidebound lesions unable to pinch, 2 patients had severe 
ulcerations, and 3 generalized pruritus. Additional severe 
cGVHD targets included joints and fascia with restricted 
range of motion (n = 4), the lung (n = 3), eyes (n = 2), mouth 
(n = 1), and gastrointestinal tract (n = 1). Additional cGVHD 
targets with mild or moderate severity are also summa-
rized in Table 2.
Patient #5 was diagnosed with severe cutaneous scGVHD, 
moderate joints and fascia and mild gastrointestinal in-
volvement 23 months after allogeneic transplantation. He 
started imatinib treatment with very good tolerance and 
no adverse events. At the first response assessment, three 
months after the start of imatinib, his sclerotic features 
started improving and by six months he had achieved par-
tial response with objective improvement in erythema 
due to fasciitis, joint stiffness, and photographic range of 
motion. His sclerotic features continued to progressively 
improve and additional immunosuppressive treatment 
was stopped 34 months later. After 49 months on 
tABle 1. Patients’, transplant, and graft-vs-host disease (GVhD) characteristics*
Patient # 1 2 3 4 5 6 7 8
Sex Female Male Female Male Male Male Male Female
Age at SCT 58 28 27 57 67 60 30 50
Disease status at 
SCT





MAC (Cy-TBI) MAC (Cy-TBI) MAC (FLAG-
Ida, Mel)
RIC (Flu-Bu) RIC (Flu-Bu) MAC (Bu-Cy)MAC (Cy-TBI)
GVHD prophylaxis CyA, MTX CyA, MTX CyA, MTX, 
ATG



















































Acute GVHD No Grade III.
Cutaneous
Response to CS
No No No No No No
cGVHD onset, 
m after SCT
De novo, 9 Quiescent, 5 De novo, 10 De novo, 16 De novo, 22 De novo, 22 De novo, 10 De novo, 7
IS before TKI CyA 3mg/Kg/d, 
MMF 1gr/8h, CS
CyA 3mg/Kg/d, 























*AMl – acute myeloid leukemia; AtG – antithymocyte globulin; Bu – busulfan; CR – complete remission; CS – corticosteroids; Cy – cyclophosph-
amide; CyA – cyclosporine A; FlAG-Ida – fludarabine, cytarabine, idarubucin, Flu – fludarabine; hl - hodgkin lymphoma; IS – immunosuppression; 
m – months; MAC – myeloablative conditioning; Mel – melphalan; MM – multiple myeloma; MMF – mofetil mycophenolate; MtX – methrotexate; PR 
– partial remission; PuVA – Psolaren-uV-A therapy; RIC – reduced intensity conditioning; SCt – stem cell transplantation; tBI – total body irradiation; 
tKI – tyrosine kinase inhibitors.
†Patient #1 required a second donor infusion (7.6x106/Kg CD34+ previous 1mg/Kg AtG on days -2 to -1 and CyA) on day +64 because of primary graft 
failure.
‡Patient #7 required three chemotherapy treatment lines (ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; eShAP: etoposide, cisplatin, 
cytarabine, methylprednisolone, and COPP: cyclophosphamide, vincristine, procarbazine, prednisone) to achieve the first unconfirmed complete 
remission.
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tABle 2. tKI treatment and scGVhD assessment before the start of tKI treatment (PRe) and at withdrawal or death (POSt) according to nIh updated 
criteria (24)
Patient # 1 2 3 4 5 6 7 8
Main cGvHD 
targets
Skin, lung, joints Skin, joints, eyes, 
mouth
Skin, joints Skin, joints Skin, joints Skin, lung, gi 
tract, mouth, eyes
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90% / 0%† 100% 100% NA 100% 100% 100% NA (refractori-
ness and discon-
tinued)
















Time from SCT, m 22 32 21 19 23 98‡ 23 34
Time from scGVHD 
onset, m

































































































2 1 3 0 3 0 2 2 2 0 0 0 3 0 3 3
shoulder 3 4 4 7 5 7 7 7 5 7 4 7 3 3
elbow 4 5 5 7 5 7 5 5 5 7 5 7 4 4
wrist/finger 6 6 5 7 2 7 3 3 5 7 5 7 2 2
ankle 4 4 4 4 1 4 4 4 4 4 3 4 2 2
Skin; features score3 3 3 2 3 2 3 3 3 0 3 2 3 2 3 3
score % BSA 2 2 2 1 3 1 2 2 2 0 2 2 2 1 2 2
deep sclerosis Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
hidebound Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
superficial sclerosis Yes Yes Yes Yes
hyperpigmenta-
tion
Yes Yes Yes Yes Yes
hypopigmentation Yes Yes Yes Yes Yes Yes
lichen planus-like Yes Yes
poikiloderma Yes Yes Yes Yes Yes Yes
pruritus Yes Yes Yes
Hair Yes Yes Yes Yes Yes Yes
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imatinib, he achieved complete remission and treatment 
was withdrawn. At the last follow-up, 22 months after ima-
tinib withdrawal, he remained off immunosuppression and 
in complete scGVHD and primary disease remission.
5 patients (62.5%) were resistant and/or developed gastro-
intestinal intolerance to imatinib after a median of 3 (range, 
1-8) months, which required treatment discontinuation, 
and 1 case (patient #4) developed grade IV neutropenia 
two weeks after the start of treatment, which resolved af-
ter imatinib withdrawal. Finally, there was 1 non-relapse 
death (patient #6) 35 months after the start of imatinib 
treatment due to an acute pulmonary complication and a 
subsequent septic shock of unknown origin. At the time of 
death, he remained on a stable partial response of scGVHD 
with NIH scores improvement in all target organs (the skin, 
lung, mouth, gastrointestinal tract, and eyes) and his pri-
mary disease was in complete remission 133 months after 
transplantation (Table 2). The response rate (partial and/or 
complete responses) (24) for severe scGVHD in our series 
was 25% for imatinib (2/8).
5 patients resistant or intolerant to imatinib started dasat-
inib treatment. 3 of them had already experienced disease 
response at the first response assessment three months 
after the start of dasatinib (patients #2, #3, and #7) as as-
sessed by a decrease in NIH skin, joints and fascia, mouth, 
and eyes scores, increase in photographic range of mo-
tion scores, improvement in Karnofsky Performance Status, 
and resolution of skin ulcers. Dasatinib was very well tol-
erated, with no adverse events. At the consecutive quar-
terly response assessments, scGVHD continued improving, 
leading to a discontinuation of dasatinib treatment in all 
three cases in a median of 57 months (range, 26-75) after 
the start of treatment. These patients had already discon-
tinued corticosteroids and all additional immunosuppres-
sive treatments, except the patient #2, who continued to 
receive low doses of mofetil mycophenolate. At the last 
follow-up, all three patients were alive and continued to 
have good scGVHD response with no requirement for ad-
ditional immunosuppressive treatment and their primary 
disease in complete remission for a median of 95 months 
(range, 68-103) after transplantation. One patient (patient 
#1) achieved partial response three months after the start 
of dasatinib treatment with improvement in sclerotic fea-
tures, skin thickness, joint mobility, and pulmonary in-
volvement. By 12 months of dasatinib treatment she 
had become oxygen-independent at rest and her 
Nails Yes Yes Yes Yes Yes Yes

















Mouth; NIH score 0 0 2 0 0 0 0 0 0 0 2 1 0 0 3 3
Genital tract score 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
Gastrointestinal 
tract
0 0 0 0 0 0 0 0 1 0 3 1 0 0 2 2
Eyes 0 0 3 0 0 0 0 0 0 0 3 1 0 0 2 2
Status at the last 
follow-up
Dead Alive Alive Alive Alive Dead Alive Alive



















Months after SCT 50 95 103 81 92 133 68 36
*BSA – body surface area; CS – corticosteroids; gi – gastrointestinal; FeV1 – forced expiratory volume in 1 second; IS – immunosuppression; m – months; nA – not ap-
plicable; PRe – national Institutes of health (nIh) scores before the start of tKI treatment; POSt – nIh scores at withdrawal of tKI treatment or death; P-ROM – photo-
graphic range of motion; scGVhD – sclerotic chronic graft-vs-host disease, SCt – stem cell transplantation; tKI – tyrosine kinase inhibitors.
†Patient #1 achieved a durable partial response with 90% reduction of her initial corticosteroid dose with a consecutive severe cGVhD flare; corticosteroid treatment 
was then restarted, but the patient died 28 mo after starting dasatinib treatment due to rapid pulmonary cGVhD progression.
‡In patient #6 immunosuppression was restarted in January 2007.
tABle 2. Continued. tKI treatment and scGVhD assessment before the start of tKI treatment (PRe) and at withdrawal or death (POSt) according to 
nIh updated criteria (24)
Patient # 1 2 3 4 5 6 7 8
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initial corticosteroid dose had been reduced by more than 
90% (20). However, two months later her pulmonary symp-
toms started worsening, with progressive shortness of 
breath and oxygen requirement. Corticosteroid treatment 
was restarted, but she died 28 months after the start of 
dasatinib treatment due to rapid pulmonary cGVHD pro-
gression. Finally, patient #8 previously intolerant to ima-
tinib, continued to have a stable disease after 2.5 months 
on dasatinib, showing objective improvement in body 
surface area involved by deep sclerotic features although 
not measurable by NIH skin score. However, dasatinib had 
to be discontinued due to grade 2 nausea and vomiting. 
At the time of dasatinib withdrawal and compared to the 
previous month, her cGVHD symptoms were a little better 
(+1) and the cGVHD severity grade had decreased from 8 
to 6 despite the fact that both the clinician and the pa-
tient reported that perceived severity of sclerosis did not 
decrease, being thus far, severe (24) (data not shown). At 
the last follow-up, 5 patients had been on dasatinib for a 
median of 28 months (range, 2.5-75), with no grade 3-4 
adverse events and a very good tolerance. Only 1 patient 
(#8) required early treatment discontinuation due to grade 
2 gastrointestinal intolerance. We observed 3 partial re-
sponses to dasatinib (60%, 3/5) according to NIH (24) and 
1 stable disease (20%). An additional patient (20%) showed 
partial response during 27 months, with a consecutive se-
vere cGVHD flare and death.
There were 2 infectious complications (pneumococcal 
meningitis in patient #3 while on dasatinib with good re-
sponse to antibiotic treatment and septic shock and death 
in patient #6 while on imatinib), in 5 patients corticosteroid 
treatment could be withdrawn, and all patients had a com-
plete response of their primary disease at the last follow-
up (Table 2).
Overall, 5 patients (62.5%, 2 on imatinib and 3 on dasat-
inib) achieved partial or complete responses of scGVHD 
(24). The response rate for imatinib was 25% (2/8; 1 patient 
was able to discontinue TKI and all additional immunosup-
pressive treatments) and 60% for dasatinib (3/5; 3 patients 
were able to discontinue TKI and 2 all additional immuno-
suppressive treatments). Overall, 6 patients were alive at 
the last follow-up. a median of 86.5 months (range 36-103) 
after transplantation.
DISCuSSIOn
In our series, the response rate (partial and/or complete 
responses) for severe scGVHD was 60% for dasatinib 
and 25% for imatinib. The most common adverse event re-
lated to imatinib that required treatment discontinuation 
was gastrointestinal intolerance. Olivieri et al (14) also re-
ported toxicities occurring during the first three months of 
treatment. Baird et al (15) described the poor gastrointes-
tinal tolerance of imatinib when administered at the dos-
es of 200 mg or greater. Therefore, the high gastrointesti-
nal toxicity associated to imatinib in our study could have 
been related to the higher dose administered.
On the other hand, dasatinib was very well tolerated in our 
series, with only a single case of grade 2 gastrointestinal 
intolerance. At scGVHD diagnosis, 6 patients had severe 
scoring attributable to multiple severe organ involvement. 
3 of them had severe joint and range of motion limitation 
and severe cutaneous sclerotic features. According to NIH 
severity scores changes, the joint and fascia and the pho-
tographic range of motion scores showed complete re-
sponse to dasatinib (24), however their skin NIH grading 
only decreased to a score of 2 on the NIH 0-3 point-scale 
(23), as residual superficial sclerotic features were still pres-
ent at the last-follow-up. Thus, the global severity score just 
decreased from severe to moderate but patients’ range of 
motion normalized and their sclerosis, quality of life, and 
performance status significantly improved, enabling with-
drawal of additional immunosuppressive treatments.
Our data suggest that dasatinib may be considerably bet-
ter tolerated and a more effective therapeutic option than 
imatinib for patients with refractory scGVHD. Dasatinib 
was safer than imatinib, steroid-sparing, and had a low in-
cidence of infectious complications. However, the admin-
istration of high doses of imatinib could have in part ac-
counted for the high gastrointestinal toxicity. Therefore, 
lower doses of imatinib may be recommended.
ScGVHD is often refractory to standard immunosuppres-
sive treatments and remains a significant problem for 
many long-term survivors. First and second generation TKI 
target fibrotic signaling pathways that cause organ fibrosis, 
representing a potential valuable salvage therapy for pa-
tients with refractory scGVHD. Advantages of TKI treatment 
include a well-established safety profile, an easy manage-
ment of drug interactions, and an oral route of adminis-
tration, a feature considerably important for patients’ and 
their quality of life. Treatment of scGVHD with antifibrot-
ic drugs that block the kinase fibrotic pathway may be a 
safe and effective therapeutic option. However, the small 
number of patients in our series is a significant limitation, 
and many additional issues remain unexplained, such as 
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the pathophysiology of scGVHD and the factors predicting 
the successful use of TKI in this setting. This is emphasized 
in an interesting case report by Pulanic et al (25), where an 
allogeneic stem cell transplant recipient developed severe 
scGVHD while on dasatinib treatment due to persistence 
of residual chronic myeloid leukemia after transplant. Fur-
ther larger studies and clinical trials are warranted to de-
termine appropriate patient selection, optimal doses, and 
duration of therapy for immunosuppressed patients.
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